U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858579) titled 'A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)' on Feb. 18.
Brief Summary: The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Study Start Date: Feb. 10
Study Type: INTERVENTIONAL
Condition:
Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
DRUG: DNTH103
IV Infusion
DRUG: DNTH103
SC injection
DRUG: Placebo
SC injection
Recruitment Status: RECRUITING
Sponsor: Dianthus Therapeutics
Published by HT Di...